<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03223272</url>
  </required_header>
  <id_info>
    <org_study_id>130822008</org_study_id>
    <nct_id>NCT03223272</nct_id>
  </id_info>
  <brief_title>Mechanisms of Refractory Hypertension (Reserpine)</brief_title>
  <official_title>Mechanisms of Refractory Hypertension (Reserpine)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is deigned to determine if refractory hypertension is attributable to heightened
      sympathetic tone by quantifying the antihypertensive benefit of reserpine, a sympatholytic
      agent, in patients failing other classes of antihypertensive agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with refractory hypertension, defined as uncontrolled office blood pressure despite
      use of 5 or more antihypertensive agents, including a thiazide diuretic and spironolactone,
      will be randomized to open-label reserpine 0.1 mg daily for 4 weeks. If tolerated, the dose
      of the reserpine will be increased to 0.25 mg daily for an additional 4 weeks. Twenty-four
      hour ambulatory blood pressure monitoring will be done at baseline, after the initial 4-week
      treatment period, and at the end of the 8-week treatment period. All other antihypertensive
      medications will remain unchanged during the 8-week treatment period. The primary endpoint
      will be change in 24-hr ambulatory systolic blood pressure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2015</start_date>
  <completion_date type="Anticipated">July 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, dose titration study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ambulatory Systolic Blood Pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Twenty-four ambulatory systolic blood pressure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Refractory Hypertension</condition>
  <arm_group>
    <arm_group_label>Reserpine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive open-label reserpine 0.1 mg daily for - weeks; titrating to 0.25 mg daily for additional 4-weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reserpine</intervention_name>
    <description>Open label reserpine 0.1-0.25 mg pill orally</description>
    <arm_group_label>Reserpine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - adult with refractory hypertension defined as uncontrolled office blood pressure with use
        of 5 or more hypertensive agents, including a thiazide diuretic and spironolactone

        Exclusion Criteria:

          -  congestive heart failure (EF 40%)

          -  chronic kidney disease (GFR &lt;40 ml/min/1.73 mm)

          -  stroke and/or myocardial infarction or acute CHF exacerbation within last 3 months

          -  ongoing depression

          -  active peptic ulcer disease

          -  bradycardia &lt;50 beats per minute

          -  2nd or 3rd degree heart block

          -  known intolerance of reserpine

          -  use of digoxin or tricycle antidepressants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Calhoun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David A Calhoun, MD</last_name>
    <phone>205-934-9281</phone>
    <email>dcalhoun@uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felice Y Cook, BA</last_name>
    <phone>205-934-1400</phone>
    <email>fycook@uab.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UAB</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35292</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David A Calhoun, MD</last_name>
      <phone>205-934-9281</phone>
      <email>dcalhoun@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Felice Y Cook, BA</last_name>
      <phone>205-934-1400</phone>
      <email>fycook@uab.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>David Calhoun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>sympathetic tone</keyword>
  <keyword>resperpine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reserpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>One year after study completion, de-identified subject demographic data and primary outcome data will be available by request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

